R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
TL;DR: The principal dose-limiting toxicity was myelosuppression, although in some patients a flu-like syndrome precluded dose escalation, and significant rash and mucositis also frequently occurred in toxic patients.
Journal ArticleDOI
Effects of the Differentiating Agent Hexamethylene Bisacetamide on Normal and Myelodysplastic Hematopoietic Progenitors
Eric K. Rowinsky,Ross C. Donehower,Jerry L. Spivak,Philip J. Burke,Constance A. Griffin,Richard J. Jones +5 more
TL;DR: Similar inhibitory effects of HMBA on normal and abnormal hematopoietic progenitors suggest that HMBA may be of limited utility in producing and sustaining elevations of peripheral blood cell counts in patients with myelodysplastic syndrome.
Journal ArticleDOI
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
William Slichenmyer,Ross C. Donehower,T L Chen,M K Bowling,William P. McGuire,Eric K. Rowinsky +5 more
TL;DR: Results show that the H2RAs cimetidine and famotidine do not differentially affect the pharmacologic and toxicity profiles of paclitaxel when used in the premedication regimen to prevent major hypersensitivity reactions, and may be interchanged.
Journal Article
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
TL;DR: The paclitaxel/cyclophosphamide combination is potentially attractive because of the significant single-agent activity of both drugs against metastatic breast cancer and the paucity of shared nonhematologic toxicities.
Journal ArticleDOI
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
David S. Ettinger,Dianne M. Finkelstein,Ross C. Donehower,A Y Chang,Michael Cerny Green,Ronald H. Blum,Richard G. Hahn,John C. Ruckdeschel +7 more
TL;DR: One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin.